GlaxoSmithKline Pharmaceuticals Limited (GSK India) announced its financial results for the quarter ended 30th September 2026 through a press release dated 3rd November 2026. The disclosure was submitted to BSE Limited and The National Stock Exchange of India Limited under the signature of Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary.

Financial Performance

  • Revenue for Q2 FY2027 stood at ₹1180 crore, representing 21% year-over-year growth
  • Profit After Tax (PAT) increased by 31% to ₹335 crore
  • EBITDA grew by 20% compared to the same quarter last year
  • Growth was supported by a favorable base effect, as the corresponding period last year was impacted by supply constraints and GST-related transition effects

Portfolio Performance

General Medicines Portfolio:

  • Delivered strong growth with key promoted brands outperforming their respective markets (Evolution Index >100)
  • Established brands including Augmentin, Calpol, Ceftum and T-bact gained market share and strengthened leadership positions
  • Introduced line extensions: Calpol 500 Suspension and Eltroxin 62.5 mcg and 150 mcg formulations for more precise dosing

Respiratory Portfolio:

  • Nucala (mepolizumab) and Trelegy Ellipta gained traction through expanding access pathways
  • Continued support for patients with chronic respiratory diseases

Vaccines Business:

  • Delivered continued growth, led by leadership in private self-pay paediatric vaccines market
  • Advanced adult vaccination ecosystem awareness, particularly for adults above 50 years with cardiovascular and metabolic conditions
  • Strong uptake of Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted)
  • Achieved Guinness World Records™ title for "Largest Brochure Mosaic-Image" on World Heart Day (September 29) using pledge cards from over 5,000 healthcare professionals

Oncology Portfolio:

  • Showed accelerated momentum with Jemperli (dostarlimab) and Zejula (niraparib) benefiting from first full year of market presence
  • Addressing significant unmet needs in gynaecological cancers
  • Announced upcoming foray into haemato-oncology with launch of BLENREP (belantamab mafodotin), an anti-BCMA antibody-drug conjugate (ADC)
  • BLENREP is indicated for relapsed or refractory multiple myeloma as combination therapy in adult patients who have received at least one prior therapy (Blenrep Prescribing Information, India, Version: BRP/PI/IN/2026/01, Dated: 15-Apr-2026)

Management Commentary

Bhushan Akshikar, Managing Director, GSK India, stated that the strong performance reflects robust execution of the strategy to build a science-first, innovation-led business. He highlighted resilient growth across the diversified portfolio, strength of trusted brands, and increasing contribution of innovative therapies.

Akshikar also noted that the company continues to accelerate efforts on late-stage pipeline assets, build momentum for key launches across Oncology and Adult Vaccination, and simplify ways of working. He acknowledged dynamic geopolitical environment driving inflationary pressures and supply chain risks, emphasizing focus on building business resilience.

Operational Updates

The company continues to enhance supply chain resilience through:

  • Diversified sourcing strategies
  • Strengthened contingency planning
  • Improved end-to-end visibility across key operations
  • These measures have helped restore local and global supply chains to sustainable operating levels